Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cinclus Pharma Holding AB ( (SE:CINPHA) ) has provided an update.
Cinclus Pharma announced that it will present data on its optimized linaprazan glurate tablet formulation at the United European Gastroenterology Week in Berlin. The new formulation shows a two-fold increase in bioavailability, which is encouraging for the ongoing Phase III study, potentially enhancing the company’s position in the GERD treatment market.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing drugs for acid-related diseases and disorders of the upper gastrointestinal tract. Its leading drug candidate, linaprazan glurate, is designed to treat gastroesophageal reflux disease (GERD) more effectively than current treatments, addressing a significant unmet need in the market.
Average Trading Volume: 65,014
Technical Sentiment Signal: Buy
Find detailed analytics on CINPHA stock on TipRanks’ Stock Analysis page.